ABUS vs NWS · P/E 5.4, rev $6.2M vs rev $9.03B
Arbutus Biopharma Corp (ABUS) versus NWS (NWS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
NWS (NWS) common stock.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported NWS revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 6.8% from 2025-06-30 to 2026-06-30. NWS currently screens at market cap $0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. NWS currently screens at market cap $0.
Not investment advice. Open the ABUS and NWS stock pages for the full models.
Not investment advice.